Physician profile
Thomas J Malvar
NPI 1851382626
$16,869.38
in general payments reported to CMS, 2019-2025
41 companies · $3,605 in 2025
The $3,605 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,247 · 2020: $1,178 · 2021: $2,035 · 2022: $2,375 · 2023: $2,811 · 2024: $3,617 · 2025: $3,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $31.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,002.01 |
| Education | $31.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,073.37 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $2,072.56 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,923.06 | 2021-2025 | |
| Novo Nordisk INC | $1,359.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,085.05 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $916.75 | 2021-2025 | |
| Glaxosmithkline, LLC. | $758.21 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $664.52 | 2019-2025 | Ofev, Jardiance, Jascayd |
| Janssen Pharmaceuticals, INC | $641.90 | 2019-2022 | |
| Exact Sciences Corporation | $593.21 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $587.73 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $503.19 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $458.57 | 2019-2025 | |
| Amarin Pharma, INC. | $394.19 | 2019-2022 | |
| Lundbeck LLC | $284.62 | 2021-2025 | Rexulti |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $264.78 | 2019-2023 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $264.74 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $260.08 | 2019-2025 | Camzyos, Eliquis |
| Paratek Pharmaceuticals, INC. | $159.48 | 2024-2025 | Nuzyra |
| Abbott Laboratories | $154.95 | 2021-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $140.46 | 2019-2022 | |
| Eisai INC. | $139.86 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $130.82 | 2025 | Rexulti |
| Daiichi Sankyo INC. | $129.19 | 2020-2023 | Injectafer |
| Amphastar Pharmaceuticals, INC. | $108.51 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $101.04 | 2023-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $96.08 | 2020-2023 | Nexletol |
| Alkermes, INC. | $86.57 | 2024 | Vivitrol |
| Mylan Specialty L.P. | $84.50 | 2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $63.49 | 2023-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $58.83 | 2024-2025 | Veozah |
| Axsome Therapeutics, INC. | $52.54 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $47.43 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $44.01 | 2019-2025 | Trintellix |
| Avanir Pharmaceuticals, INC. | $32.94 | 2021 | |
| Almatica Pharma LLC | $31.54 | 2022-2025 | Loreev Xr, Teriparatide |
| Currax Pharmaceuticals LLC | $30.54 | 2022-2024 | Onzetra Xsail, Contrave |
| Biogen, INC. | $20.82 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.66 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.84 | 2025 | |
| Seqirus USA INC | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Malvar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.